Scaling/Widening of AUC [Regulatives / Guidelines]

posted by Researcher101 – Egypt, 2021-02-23 21:40 (713 d 08:35 ago) – Posting: # 22224
Views: 2,731

I'm asking if there is any guidance allowing scaling of AUC in case of highly variable drugs and what is the range of scaling if applicable


Edit: See this post #3. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
21 visitors (0 registered, 21 guests [including 10 identified bots]).
Forum time: 06:15 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5